Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 02:26PM ET
1.35
Dollar change
+0.02
Percentage change
1.28
%
Index- P/E3.06 EPS (ttm)0.44 Insider Own27.80% Shs Outstand53.00M Perf Week5.23%
Market Cap72.72M Forward P/E- EPS next Y-1.20 Insider Trans-1.51% Shs Float38.98M Perf Month-8.99%
Income23.40M PEG0.08 EPS next Q-0.38 Inst Own21.81% Short Float1.24% Perf Quarter-20.30%
Sales100.20M P/S0.73 EPS this Y-394.57% Inst Trans-5.11% Short Ratio2.49 Perf Half Y-0.96%
Book/sh1.79 P/B0.75 EPS next Y5.26% ROA16.70% Short Interest0.48M Perf Year-15.81%
Cash/sh1.52 P/C0.88 EPS next 5Y36.90% ROE29.06% 52W Range0.99 - 1.89 Perf YTD-8.37%
Dividend Est.- P/FCF- EPS past 5Y- ROI23.46% 52W High-28.73% Beta0.64
Dividend TTM- Quick Ratio3.35 Sales past 5Y586.08% Gross Margin99.13% 52W Low36.06% ATR (14)0.06
Dividend Ex-Date- Current Ratio3.35 EPS Y/Y TTM149.19% Oper. Margin16.22% RSI (14)41.42 Volatility5.16% 4.25%
Employees46 Debt/Eq0.05 Sales Y/Y TTM104.19% Profit Margin23.36% Recom1.67 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q6.29% Payout0.00% Rel Volume0.25 Prev Close1.33
Sales Surprise-56.96% EPS Surprise-454.27% Sales Q/Q468.11% EarningsMay 15 AMC Avg Volume194.54K Price1.35
SMA20-3.75% SMA50-9.23% SMA200-4.39% Trades Volume38,218 Change1.28%
Date Action Analyst Rating Change Price Target Change
Sep-23-22Upgrade Evercore ISI In-line → Outperform $2 → $8
Oct-01-21Downgrade Oppenheimer Outperform → Perform
Jan-22-21Reiterated H.C. Wainwright Buy $33 → $40
Dec-16-20Initiated Berenberg Buy $47
Sep-29-20Initiated Evercore ISI Outperform
Nov-05-19Reiterated H.C. Wainwright Buy $28 → $35
Sep-09-19Initiated Janney Buy
Feb-09-18Initiated Cantor Fitzgerald Overweight $27
Nov-27-17Initiated Stifel Buy $26
Nov-27-17Initiated Oppenheimer Outperform $30
Jun-03-24 04:05PM
May-16-24 04:05PM
May-15-24 08:55PM
04:05PM
May-08-24 08:00AM
04:07PM Loading…
May-01-24 04:07PM
Apr-16-24 11:52AM
Mar-15-24 12:51PM
Mar-14-24 06:33AM
Mar-13-24 05:10PM
04:01PM
Mar-06-24 08:05AM
Feb-28-24 08:05AM
Feb-26-24 08:05AM
Feb-05-24 11:27PM
04:05PM Loading…
Jan-31-24 04:05PM
Jan-29-24 04:07AM
Jan-25-24 04:40AM
Jan-05-24 08:05AM
Jan-02-24 08:05AM
Nov-14-23 09:02AM
Nov-13-23 04:05PM
Nov-06-23 08:05AM
Nov-01-23 04:05PM
08:05AM
Oct-31-23 04:05PM
Oct-18-23 12:00PM
Sep-29-23 04:05PM
Sep-20-23 04:05PM
Sep-16-23 01:01PM
08:00AM Loading…
Sep-12-23 08:00AM
Sep-06-23 08:05AM
Aug-31-23 04:05PM
Aug-29-23 12:00PM
Aug-22-23 05:45PM
Aug-13-23 05:24AM
Aug-11-23 06:32AM
Aug-10-23 06:05PM
04:05PM
Aug-03-23 08:05AM
Jul-31-23 08:05AM
Jul-05-23 06:20AM
Jun-30-23 04:05PM
Jun-18-23 07:51PM
Jun-14-23 08:05AM
May-31-23 04:05PM
May-18-23 07:09AM
May-16-23 11:36AM
May-12-23 05:30AM
May-11-23 05:35PM
04:05PM
May-04-23 08:05AM
Apr-28-23 04:05PM
Apr-26-23 08:05AM
Apr-17-23 07:14AM
Apr-14-23 08:05AM
Apr-13-23 06:19AM
Apr-05-23 09:59PM
Apr-01-23 09:07AM
Mar-31-23 04:05PM
Mar-30-23 06:05PM
04:05PM
Mar-13-23 08:05AM
Mar-06-23 08:05AM
Feb-28-23 04:05PM
08:05AM
Feb-23-23 09:35AM
Feb-22-23 09:35AM
Jan-31-23 04:05PM
Jan-14-23 08:03AM
Dec-22-22 04:05PM
Nov-22-22 08:05AM
Nov-16-22 05:55AM
Nov-14-22 05:25PM
04:05PM
Nov-08-22 08:05AM
Nov-07-22 08:05AM
Nov-02-22 10:01AM
Oct-19-22 08:05AM
Oct-03-22 08:05AM
Sep-25-22 07:00AM
Sep-23-22 11:02AM
Sep-22-22 11:30AM
10:53AM
07:20AM
02:00AM
Sep-15-22 04:05PM
Sep-07-22 12:37PM
10:36AM
08:05AM
Sep-06-22 10:10AM
08:05AM
Sep-05-22 06:49AM
Aug-25-22 09:55AM
Aug-10-22 05:25PM
04:05PM
Aug-09-22 08:05AM
Jul-06-22 02:30AM
Jun-27-22 04:27PM
04:05PM
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shukla SathCEO and PresidentFeb 05 '24Sale1.4545,09365,3851,176,007Feb 05 08:40 PM
Mahadevia AnkitDirectorFeb 02 '24Sale1.3763,79587,399744,997Feb 05 08:50 PM
JOSEPH TAMARA LChief Legal OfficerFeb 02 '24Sale1.3730,90642,341531,615Feb 05 08:48 PM
Shukla SathCEO and PresidentFeb 02 '24Sale1.3730,90142,3341,221,100Feb 05 08:40 PM
Keutzer TimothyChief Operating OfficerFeb 02 '24Sale1.3630,97142,121534,050Feb 05 08:53 PM
HAMED KAMALChief Medical OfficerFeb 02 '24Sale1.3728,07538,463788,117Feb 05 08:45 PM
HAMED KAMALChief Medical OfficerSep 13 '23Sale1.2739,49650,160576,461Sep 15 05:47 PM
Shukla SathCEO and PresidentAug 29 '23Sale1.304,1635,412572,500Aug 30 04:20 PM
Mahadevia AnkitDirectorAug 28 '23Sale1.269,04011,390788,792Aug 30 04:21 PM
JOSEPH TAMARA LChief Legal OfficerAug 28 '23Sale1.261,8542,336322,790Aug 30 04:22 PM
Keutzer TimothyChief Development OfficerAug 28 '23Sale1.261,8542,336325,290Aug 30 04:23 PM
Shukla SathCEO and PresidentAug 28 '23Sale1.261,8542,336576,663Aug 30 04:20 PM